MDxHealth S.A. (MDXH)

Shares of MDxHealth SA (NASDAQ: MDXH - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The

Shares of MDxHealth SA (NASDAQ: MDXH - Get Free Report) have received a consensus rating of "Moderate Buy" from the five analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among

MDxHealth SA ( MDXH ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Michael McGarrity - CEO & Executive Director Scott McMahan - Vice President of Finance and Accounting Conference Call Participants John Fraunces - Lifesci Advisors, LLC Daniel Brennan - TD Cowen, Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the MDxHealth Third Quarter 2025 Earnings Conference Call.

If you are looking for stocks that are well positioned to maintain their recent uptrend, MDxHealth SA (MDXH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Appointment of Executive Chairman, proposed change of name and strategy update Company to pursue revised strategy and name change to CelLBxHealth plc Dr. Jan Groen, the current Non-Executive Chairman and recognised oncology diagnostic industry veteran, to lead company as Executive Chairman Revised strategy to sharpen focus on the provision of industry-leading CTC intelligence and accelerate Company's commercial traction, whilst delivering further cost control Cash runway remains through to Q1 2026; expected need to raise funds in coming months GUILDFORD, SURREY / ACCESS Newswire / October 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that its Chairman, Dr Jan Groen, has moved into an executive role. Jan will lead the Company as it pursues a revised strategy, focused on tight cost control, accelerated commercial progress and a clear plan towards becoming a sustainable business.

MDxHealth SA (MDXH) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.31 per share a year ago.

M dxh ealth Reports Preliminary Second Quarter 202 5 Results , Reaches Positive Adjusted EBITDA , and A nnounces Acquisition of Exo some D iagnostics B usiness from Bio - Techne

IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May.

MDxHealth SA (NASDAQ:MDXH ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Corporate Participants John Fraunces - LifeSci Advisors, IR Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Mark Massaro - BTIG Dan Brennan - UBS Jason Bednar - Piper Sandler Thomas Vranken - KBC Securities Nelson Cox - Lake Street Capital Markets Operator Good day and welcome to the MDxHealth First Quarter 2025 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Mr.

MDxHealth SA (MDXH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.31 per share a year ago.

Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q&A today at 4:30 PM ET / 22:30 CET

MDxHealth SA (MDXH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

MDxHealth SA (NASDAQ:MDXH ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants John Fraunces - LifeSci Advisors, IR Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Vidyun Bais - BTIG Dan Brennan - TD Cowen Operator Good day. And welcome to the MDxHealth Fourth Quarter and Full Year 2024 Earnings Call.

MDxHealth SA (MDXH) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.39 per share a year ago.

Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 22:30 CET

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods.